Long-term effectiveness of the nine-valent human papillomavirus vaccine: Interim results after 12 years of follow-up in Scandinavian women
A pivotal study in women aged 16-26 years demonstrated that the nine-valent human papillomavirus (9vHPV) vaccine was efficacious against high-grade cervical dysplasia related to the HPV types covered by the vaccine. To evaluate whether effectiveness remains above 90% for up to 14 years post-vaccinat...
Saved in:
Main Authors: | Susanne K. Kjaer (Author), Thea E. Hetland Falkenthal (Author), Karin Sundström (Author), Christian Munk (Author), Tina Sture (Author), Oliver Bautista (Author), Sonali Rawat (Author), Alain Luxembourg (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2024-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up
by: Susanne K. Kjaer, et al.
Published: (2021) -
9-Valent human papillomavirus vaccine: a review of the clinical development program
by: Alain Luxembourg, et al.
Published: (2017) -
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial
by: Vu Dinh Thiem, et al.
Published: (2021) -
Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants
by: Suzanne M. Garland, et al.
Published: (2022) -
Human papillomavirus genotypic characteristics of 60,685 subjects under age-expansion vaccination of the nine-valent human papillomavirus vaccine: A cross-sectional study
by: Yu Liu, et al.
Published: (2023)